Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its ...

Phillip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Elias Zerhouni, Vice Chairman and ...

LEBANON, N.H., Jan. 13, 2026 /PRNewswire/ -- Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that 11 new ...

MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...

GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...

T-cell-specific surface glycoprotein CD28, also known as TP44, is a single-pass type I membrane protein that contains one Ig-like V-type (immunoglobulin-like) domain. It is a key co-stimulatory ...

There are 11 additional Adimab-associated programs that are currently in Phase II or Phase III (pivotal) trials. The total number of Adimab-associated clinical programs initiated by our partners has ...